114 related articles for article (PubMed ID: 10857997)
21. Phase II trial of Didemnin B in patients with advanced renal cell carcinoma.
Motzer R; Scher H; Bajorin D; Sternberg C; Bosl GJ
Invest New Drugs; 1990 Nov; 8(4):391-2. PubMed ID: 2084073
[TBL] [Abstract][Full Text] [Related]
22. Phase II trial of misonidazole (MISO) and cyclophosphamide (CYC) in metastatic renal cell carcinoma.
Glover D; Trump D; Kvols L; Elson P; Vogl S
Int J Radiat Oncol Biol Phys; 1986 Aug; 12(8):1405-8. PubMed ID: 3759565
[TBL] [Abstract][Full Text] [Related]
23. Phase I/II trial of 5-fluorouracil and a noncytotoxic dose level of suramin in patients with metastatic renal cell carcinoma.
George S; Dreicer R; Au JJ; Shen T; Rini BI; Roman S; Cooney MM; Mekhail T; Elson P; Wientjes GM; Ganapathi R; Bukowski RM
Clin Genitourin Cancer; 2008 Sep; 6(2):79-85. PubMed ID: 18824429
[TBL] [Abstract][Full Text] [Related]
24. Phase II trial of continuous once-daily dosing of sunitinib as first-line treatment in patients with metastatic renal cell carcinoma.
Barrios CH; Hernandez-Barajas D; Brown MP; Lee SH; Fein L; Liu JH; Hariharan S; Martell BA; Yuan J; Bello A; Wang Z; Mundayat R; Rha SY
Cancer; 2012 Mar; 118(5):1252-9. PubMed ID: 21898376
[TBL] [Abstract][Full Text] [Related]
25. Sunitinib in patients with metastatic renal cell carcinoma.
Motzer RJ; Rini BI; Bukowski RM; Curti BD; George DJ; Hudes GR; Redman BG; Margolin KA; Merchan JR; Wilding G; Ginsberg MS; Bacik J; Kim ST; Baum CM; Michaelson MD
JAMA; 2006 Jun; 295(21):2516-24. PubMed ID: 16757724
[TBL] [Abstract][Full Text] [Related]
26. Single institution experience with recombinant gamma-interferon in the treatment of patients with metastatic renal cell carcinoma.
Mani S; Poo WJ
Am J Clin Oncol; 1996 Apr; 19(2):149-53. PubMed ID: 8610639
[TBL] [Abstract][Full Text] [Related]
27. Phase II trial of titanocene dichloride in advanced renal-cell carcinoma.
Lümmen G; Sperling H; Luboldt H; Otto T; Rübben H
Cancer Chemother Pharmacol; 1998; 42(5):415-7. PubMed ID: 9771957
[TBL] [Abstract][Full Text] [Related]
28. Phase I trial of the histone deacetylase inhibitor, depsipeptide (FR901228, NSC 630176), in patients with refractory neoplasms.
Sandor V; Bakke S; Robey RW; Kang MH; Blagosklonny MV; Bender J; Brooks R; Piekarz RL; Tucker E; Figg WD; Chan KK; Goldspiel B; Fojo AT; Balcerzak SP; Bates SE
Clin Cancer Res; 2002 Mar; 8(3):718-28. PubMed ID: 11895901
[TBL] [Abstract][Full Text] [Related]
29. Phase-II trial of 4-demethoxydaunorubicin (DMDR) for advanced hypernephroma.
Scher HI; Yagoda A; Ahmed T; Budman D; Sordillo P; Watson RC
Cancer Chemother Pharmacol; 1985; 14(1):79-80. PubMed ID: 3855289
[TBL] [Abstract][Full Text] [Related]
30. A phase I trial of marcellomycin with a weekly dose schedule.
Joss RA; Kaplan S; Goldhirsch A; Varini M; Brunner KW; Cavalli F
Eur J Cancer Clin Oncol; 1983 Apr; 19(4):455-9. PubMed ID: 6683183
[TBL] [Abstract][Full Text] [Related]
31. Antitumor activity and safety of tivozanib (AV-951) in a phase II randomized discontinuation trial in patients with renal cell carcinoma.
Nosov DA; Esteves B; Lipatov ON; Lyulko AA; Anischenko AA; Chacko RT; Doval DC; Strahs A; Slichenmyer WJ; Bhargava P
J Clin Oncol; 2012 May; 30(14):1678-85. PubMed ID: 22493422
[TBL] [Abstract][Full Text] [Related]
32. Phase II trial of echinomycin for the treatment of advanced renal cell carcinoma. A Southwest Oncology Group study.
Marshall ME; Wolf MK; Crawford ED; Taylor S; Blumenstein B; Flanigan R; Meyers FJ; Hynes HE; Barlogie B; Eisenberger M
Invest New Drugs; 1993; 11(2-3):207-9. PubMed ID: 8262733
[TBL] [Abstract][Full Text] [Related]
33. Phase II trial of irofulven (6-hydroxymethylacylfulvene) for patients with advanced renal cell carcinoma.
Berg WJ; Schwartz L; Yu R; Mazumdar M; Motzer RJ
Invest New Drugs; 2001; 19(4):317-20. PubMed ID: 11561691
[TBL] [Abstract][Full Text] [Related]
34. Phase II evaluation of merbarone in renal cell carcinoma.
Flanigan RC; Saiers JH; Wolf M; Kraut EH; Smith AY; Blumenstein B; Crawford ED
Invest New Drugs; 1994; 12(2):147-9. PubMed ID: 7860233
[TBL] [Abstract][Full Text] [Related]
35. Phase II trial of irinotecan in combination with amifostine in patients with advanced colorectal carcinoma.
Delioukina ML; Prager D; Parson M; Hecht JR; Rosen P; Rosen LS
Cancer; 2002 Apr; 94(8):2174-9. PubMed ID: 12001114
[TBL] [Abstract][Full Text] [Related]
36. Safety and efficacy of PF-3512676 for the treatment of stage IV renal cell carcinoma: an open-label, multicenter phase I/II study.
Thompson JA; Kuzel T; Drucker BJ; Urba WJ; Bukowski RM
Clin Genitourin Cancer; 2009 Oct; 7(3):E58-65. PubMed ID: 19815483
[TBL] [Abstract][Full Text] [Related]
37. Phase II trial of DNA methyltransferase 1 inhibition with the antisense oligonucleotide MG98 in patients with metastatic renal carcinoma: a National Cancer Institute of Canada Clinical Trials Group investigational new drug study.
Winquist E; Knox J; Ayoub JP; Wood L; Wainman N; Reid GK; Pearce L; Shah A; Eisenhauer E
Invest New Drugs; 2006 Mar; 24(2):159-67. PubMed ID: 16502349
[TBL] [Abstract][Full Text] [Related]
38. A phase I trial of weekly lomustine in patients with advanced cancer.
Koller CA; Gorski CC; Benjamin RS; Legha SS; Papadopoulos NE; Plager C
Cancer; 1994 Jan; 73(1):236-9. PubMed ID: 8275432
[TBL] [Abstract][Full Text] [Related]
39. An outpatient phase II study of subcutaneous interleukin-2 and interferon-alpha-2b in combination with intravenous vinblastine in metastatic renal cell cancer.
Pectasides D; Varthalitis J; Kostopoulou M; Mylonakis A; Triantaphyllis D; Papadopoulou M; Dimitriadis M; Athanassiou A
Oncology; 1998; 55(1):10-5. PubMed ID: 9428369
[TBL] [Abstract][Full Text] [Related]
40. Phase II trial of esorubicin in advanced renal carcinoma. Clinical Screening Group of the EROTC.
Hurteloup P; Chollet P; Roche H; Chevallier B; Cappelaere P; Van Glabbece M; Hayat M; Armand JP
Eur J Cancer Clin Oncol; 1989 Jun; 25(6):995-6. PubMed ID: 2753061
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
